Ocular Therapeutix (OCUL) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
63.7M
Gross Profit
58.1M
91.17%
Operating Income
-171.8M
-269.57%
Net Income
-193.5M
-303.67%
Balance Sheet Metrics
Total Assets
457.9M
Total Liabilities
142.6M
Shareholders Equity
315.3M
Debt to Equity
0.45
Cash Flow Metrics
Operating Cash Flow
-161.1M
Free Cash Flow
-136.0M
Revenue & Profitability Trend
Ocular Therapeutix Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 63.7M | 58.4M | 51.5M | 43.5M | 17.4M |
| Cost of Goods Sold | 5.6M | 5.3M | 4.5M | 4.4M | 2.1M |
| Gross Profit | 58.1M | 53.2M | 47.0M | 39.1M | 15.3M |
| Operating Expenses | 229.9M | 135.5M | 125.6M | 117.2M | 78.2M |
| Operating Income | -171.8M | -82.4M | -78.7M | -78.0M | -62.8M |
| Pre-tax Income | -193.5M | -80.7M | -71.0M | -6.6M | -155.6M |
| Income Tax | - | - | - | - | - |
| Net Income | -193.5M | -80.7M | -71.0M | -6.6M | -155.6M |
| EPS (Diluted) | - | -$1.02 | -$0.97 | -$0.98 | -$2.56 |
Income Statement Trend
Ocular Therapeutix Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 441.0M | 232.2M | 129.6M | 191.3M | 246.2M |
| Non-Current Assets | 16.9M | 19.8M | 19.7M | 13.6M | 15.7M |
| Total Assets | 457.9M | 252.1M | 149.3M | 204.9M | 261.9M |
| Liabilities | |||||
| Current Liabilities | 41.4M | 34.9M | 31.4M | 26.3M | 26.7M |
| Non-Current Liabilities | 101.2M | 126.0M | 82.5M | 90.6M | 159.1M |
| Total Liabilities | 142.6M | 160.9M | 113.9M | 116.9M | 185.8M |
| Equity | |||||
| Total Shareholders Equity | 315.3M | 91.1M | 35.4M | 88.0M | 76.1M |
Balance Sheet Composition
Ocular Therapeutix Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -193.5M | -80.7M | -71.0M | -6.6M | -155.6M |
| Operating Cash Flow | -161.1M | -58.2M | -48.1M | 9.0M | -139.6M |
| Investing Activities | |||||
| Capital Expenditures | -1.3M | -6.1M | -3.7M | -1.2M | -841.0K |
| Investing Cash Flow | -1.3M | -6.1M | -3.7M | -1.2M | -841.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 316.4M | 166.4M | 0 | -720.0K | 224.7M |
| Free Cash Flow | -136.0M | -76.3M | -63.3M | -66.7M | -54.4M |
Cash Flow Trend
Ocular Therapeutix Key Financial Ratios
Valuation Ratios
Forward P/E
-7.97
Price to Book
4.87
Price to Sales
21.71
PEG Ratio
-7.97
Profitability Ratios
Profit Margin
91.17%
Operating Margin
-597.47%
Return on Equity
-57.19%
Return on Assets
-27.21%
Financial Health
Current Ratio
10.22
Debt to Equity
28.66
Beta
1.41
Per Share Data
EPS (TTM)
-$1.11
Book Value per Share
$1.67
Revenue per Share
$0.36
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ocul | 1.3B | - | 4.87 | -57.19% | 91.17% | 28.66 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.